CTOS 2025 Highlights✨
Connective Tissue Oncology Society (CTOS) 2025 Annual Meeting
November 12–15, 2025 – Boca Raton, Florida
After four intensive days, this year’s CTOS Annual Meeting has ended. Once again, it proved to be the central gathering place for the international sarcoma community –bringing together physicians, healthcare professionals, researchers, industry partners, and patient advocates to discuss new scientific insights, promising clinical trial results, and emerging research ideas.
As in previous years, SPAGN hosted the Patient Advocacy Lounge, providing a dedicated space for patient representatives from around the world to connect with one another and engage directly with medical experts. The Lounge continued to serve as a vibrant forum for sharing experiences, exchanging best practices, and strengthening collaborations across the global advocacy community.
This year's highlights during and around CTOS included several highly anticipated and potentially practice-changing updates, particularly in the treatment of chondrosarcoma and GIST.
Inhibrx Biosciences – ChonDRAgon Trial (Chondrosarcoma)
Inhibrx reported positive results from their registrational Phase II ChonDRAgon trial. Ozekibart (INBRX-109), a tetravalent DR5 agonist, demonstrated a clear and clinically meaningful benefit for patients with chondrosarcoma – a rare and aggressive bone cancer with no currently approved medical treatments.
Ozekibart reduced the risk of disease progression or death by 52% compared to placebo, more than doubling median progression-free survival (5.52 months vs. 2.66 months).
The company plans to submit a Biologics License Application to the FDA in Q2 2026.
Cogent Biosciences – PEAK Trial (Second-Line GIST)
Shortly before the conference, Cogent Biosciences presented the first successful Phase III trial in over 20 years for second-line treatment of GIST. The PEAK trial evaluated the combination of bezuclastinib plus sunitinib in patients whose disease is resistant or intolerant to imatinib.
The combination nearly doubled median progression-free survival, achieving 16.5 months compared with 9.2 months for sunitinib alone.
Cogent plans to submit the therapy for FDA approval in the first half of 2026.
CTOS 2025 underscored again the importance of global collaboration across the scientific, clinical, and patient advocacy communities, and it reinforced the shared commitment to accelerating progress for all those affected by sarcoma. The momentum generated in Boca Raton this year offers real hope for better outcomes in the years ahead.